Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Phase of Trial: Phase IV
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary) ; Cisplatin; Docetaxel; Pemetrexed
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 02 Jun 2017 Results (n=66) assessing efficacy of first line chemotherapy plus Icotinib maintenance presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 07 Feb 2017 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2017.